Chennai: FDC Limited has announced the launch of ‘India’s first’ oral suspension of Favipiravir–Favenza, used to treat mild to moderate cases of Covid-19.
This prescription-only solution is currently available at all retail medical outlets and hospital pharmacies across the country, it said.
‘The Favenza suspension is unique due to its convenient loading dose (Day 1) of 18 ml in the morning and 18 ml in the evening. The results of which are equivalent to nine tablets of Favipiravir 400 mg making the process of Covid-19 treatment hassle free,’ it added.
Mayank Tikkha, general manager, business development and commercial Excellence, FDC, commented, ‘With positive cases on the rise again, now is the time to provide healthcare warriors in our country with viable options in this continuous battle against this disease. In order to combat Covid-19, we believe in offering best efficacy along with convenience to our patients and as such we have focused our efforts in making the process of Covid-19 treatment hassle-free.’